Promising new shingles vaccine enters human trials
NCT ID NCT06932523
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new recombinant shingles vaccine in healthy adults aged 40 and above. Researchers will give two doses and monitor for side effects and immune response. The trial involves 645 participants and compares the new vaccine to an existing one (Shingrix) and placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant herpes zoster vaccine (CHO cells)
What this could lead to
If successful, this could provide a new option to prevent shingles in adults 40 and older.
What could go wrong
This is an early-phase trial (phase 1/2) with 645 participants, so safety and effectiveness are not yet proven. The vaccine may cause side effects or fail to generate strong immunity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER (HZ) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hubei Provincial Center for Disease Control and Prevention
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••